What is OrthoScan?
OrthoScan operates as a global leader in the development and manufacturing of mini C-arm imaging systems. The company is fundamentally dedicated to enhancing orthopedic surgical outcomes through high-precision, innovative imaging hardware. Its product portfolio, which includes the TAU 2020, TAU 1515, TAU 1512, and VERSA systems, is engineered to address the complex diagnostic and procedural requirements of modern orthopedic clinics and hospitals. By prioritizing both image quality and operational efficiency, OrthoScan has established a robust market position, effectively bridging the gap between advanced medical technology and practical clinical application. Their business model is further bolstered by a comprehensive service network and flexible financing options, which facilitate widespread adoption of their proprietary imaging platforms.
How much funding has OrthoScan raised?
OrthoScan has raised a total of $8.5M across 2 funding rounds:
Series B
$7.5M
Debt
$1M
Series B (2008): $7.5M with participation from Aphelion Capital, River Cities Capital Funds, and California Technology Ventures, LLC
Debt (2020): $1M led by PPP
Key Investors in OrthoScan
Aphelion Capital
Aphelion Capital invests in medical technology companies across all stages and therapeutic areas, but strongly prefers investments in companies that improve quality of care while reducing costs in the company's healthcare system.
River Cities Capital Funds
RC Capital is a growth equity firm focused on building high-potential healthcare companies by leveraging the interplay of medical devices, healthcare services, and healthcare IT.
California Technology Ventures, LLC
California Technology Ventures specializes in direct investments in technology and life science companies, focusing on building world-class enterprises through an entrepreneurial approach.
What's next for OrthoScan?
Looking ahead, the recent capital allocation is expected to catalyze further innovation in OrthoScan's product pipeline. As the company transitions into its next phase of enterprise-level scaling, the focus will likely shift toward integrating advanced digital capabilities into its existing C-arm architecture. This strategic evolution aims to improve diagnostic accuracy while simultaneously reducing the total cost of care, a key metric for healthcare providers globally. By leveraging the expertise of its long-term investment partners, OrthoScan is poised to capitalize on emerging trends in medical device connectivity and data-driven surgical support, ensuring sustained value creation for stakeholders and improved patient outcomes in the orthopedic domain.
See full OrthoScan company page
